Literature DB >> 29297975

Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease.

Yu Z Zhuge1, Yi Wang1, Feng Zhang1, Cheng K Zhu1, Wei Zhang1, Ming Zhang1, Qibin He1, Jian Yang2, Jian He3, Jun Chen4, Xiao P Zou1.   

Abstract

BACKGROUND AND AIMS: Hematopoietic stem cell transplantation related hepatic vein occlusive disease (HSCT-HVOD) has been researched extensively; however, little is known about the clinical features and treatment of pyrrolizidine alkaloid-induced HVOD (PA-HVOD). This retrospective single centre study examined the clinical and laboratory characteristics of 108 patients with acute PA-HVOD and explored the efficacy of anticoagulation and TIPS therapy.
METHODS: The study included 108 consecutive patients with PA-HVOD between July 2008 and June 2016. The clinical manifestations and the results of laboratory and imaging tests were evaluated. The survival rates of patients treated with different approaches were recorded.
RESULTS: Serum total bilirubin was <34.2 μmol/L (2 mg/dL) in approximately 40% of patients. More than 90% of patients were presented with hepatomegaly, uneven liver perfusion in the balance phase, compressive stenosis of the hepatic segmental inferior vena cava and decreased peak velocity of portal vein blood flow. Severe portal hypertension was observed in all patients undergoing HVPG examination or TIPS operation. Anticoagulation therapy with low molecular weight heparin combined with warfarin was significantly more effective than liver protection and supportive therapy, and TIPS further improved the prognosis of patients who did not respond to anticoagulation therapy. The total effective rate of the anticoagulation-TIPS ladder therapeutic strategy was 91%.
CONCLUSIONS: Patients with PA-HVOD had different characteristics than those with HSCT-HVOD. Anticoagulation and TIPS treatment may be effective for patients with PA-HVOD.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  clinical characteristics; hepatic vein occlusive disease; pyrrolizidine alkaloids; treatment

Mesh:

Substances:

Year:  2018        PMID: 29297975     DOI: 10.1111/liv.13684

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

1.  Risk factors of poor prognosis in patients with pyrrolidine alkaloids induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt : Transjugular intrahepatic portosystemic shunt in patients with sinusoidal obstruction syndrome, etiology matters.

Authors:  Marta Magaz; Juan Carlos García-Pagán
Journal:  Hepatol Int       Date:  2021-03-17       Impact factor: 6.047

2.  Fasting augments pyrrolizidine alkaloid-induced hepatotoxicity.

Authors:  Jiang Ma; Chunyuan Zhang; Yisheng He; Xinmeng Chen; Ge Lin
Journal:  Arch Toxicol       Date:  2021-11-18       Impact factor: 5.153

Review 3.  Metabolism-mediated cytotoxicity and genotoxicity of pyrrolizidine alkaloids.

Authors:  Yisheng He; Lin Zhu; Jiang Ma; Ge Lin
Journal:  Arch Toxicol       Date:  2021-05-18       Impact factor: 5.153

4.  Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.

Authors:  Xuan Wang; Wei Zhang; Ming Zhang; Feng Zhang; Jiangqiang Xiao; Qin Yin; Hao Han; Taishun Li; Ge Lin; Yuzheng Zhuge
Journal:  Hepatol Int       Date:  2022-01-12       Impact factor: 9.029

5.  Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function.

Authors:  Tingting Guo; Xin Li; Xiaoqian Yang; Xiangquan Kong; Hui Liu; Tao Bai; Keshu Xu; Jin Ye; Yuhu Song
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

6.  Quantitative Analysis of CT Images in Patients with Pyrrolizidine Alkaloid-Induced Sinusoidal Obstruction Syndrome.

Authors:  Chao Wang; Xingwang Wu; Wentao Xie; Xiaofei Ren; Weiping Zhang; Jianming Xu
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379

Review 7.  Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.

Authors:  Xiao-Qian Yang; Jin Ye; Xin Li; Qian Li; Yu-Hu Song
Journal:  World J Gastroenterol       Date:  2019-07-28       Impact factor: 5.742

Review 8.  Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China.

Authors:  Lin Zhu; Chun-Yuan Zhang; Dong-Ping Li; Hu-Biao Chen; Jiang Ma; Hong Gao; Yang Ye; Ji-Yao Wang; Peter P Fu; Ge Lin
Journal:  Acta Pharmacol Sin       Date:  2020-11-05       Impact factor: 7.169

Review 9.  Hepatic veno-occlusive disease may be a rare characteristic of hepatic involvement in systemic amyloidosis: case report and literature review.

Authors:  Tong-Yin Zhu; Guan-Hui Zhou; Xin-Hua Chen; Xiao-Dong Teng; Jun-Hui Sun
Journal:  J Int Med Res       Date:  2020-02       Impact factor: 1.671

10.  Low molecular weight heparin in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: five case reports.

Authors:  Minjie Jiang; Luyuan Wang; Xiaodong Du; Miaomiao Hao; Pujun Gao
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.